Global Artificial Pancreas Devices Systems Sales 麻豆原创 Report, Competitive Analysis and Regional Opportunities 2025-2031

Publication ID:

PB504256146

Publication Date:

April 10, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,250.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Artificial Pancreas Devices Systems market size was US$ 112 million in 2024 and is forecast to a readjusted size of US$ 246 million by 2031 with a CAGR of 12.1% during the forecast period 2025-2031.
The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.

Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.

A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."

An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
Medtronic monopolizes the global Artificial Pancreas Devices Systems market, holding a share about 100%.
North America is the largest market, with a share about 60%, followed by Europe, have a share about 30 percent.
In terms of product, Threshold Suspended Device Systems is the largest segment, with a share over 60%. And in terms of application, the largest application is Hospitals
, followed by Clinics.
The global Artificial Pancreas Devices Systems market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
麻豆原创 Segmentation
By Company:
Medtronic
Bigfoot Biomedical
Beta Bionics
Admetsys
Insulet
Tandem Diabetes Care
Defymed
By Type: (Dominant Segment vs High-Margin Innovation)
Threshold Suspended Device Systems
Hybrid Closed-loop APDS
Other Systems
By Application: (Core Demand Driver vs Emerging Opportunity)
Hospitals
Clinics
By Region
Macro-Regional Analysis: 麻豆原创 Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local 麻豆原创 Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Medtronic in Europe)
- Emerging Product Trends: Threshold Suspended Device Systems adoption vs. Hybrid Closed-loop APDS premiumization
- Demand-Side Dynamics: Hospitals growth in China vs. Clinics potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus 麻豆原创s:
North America
Europe
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Artificial Pancreas Devices Systems market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis 鈥� Uncovering blue ocean markets (e.g., Hybrid Closed-loop APDS in China).
Chapter 5: Application-based segmentation analysis 鈥� High-growth downstream opportunities (e.g., Clinics in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles 鈥� Financials, product portfolios, and strategic developments.
Chapter 8: 麻豆原创 dynamics 鈥� Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled 麻豆原创 Entry: Navigate regulatory complexities in focus markets (e.g., China鈥檚 policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Threshold Suspended Device Systems dominance in Europe vs. Hybrid Closed-loop APDS demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Artificial Pancreas Devices Systems Product Scope
1.2 Artificial Pancreas Devices Systems by Type
1.2.1 Global Artificial Pancreas Devices Systems Sales by Type (2020 & 2024 & 2031)
1.2.2 Threshold Suspended Device Systems
1.2.3 Hybrid Closed-loop APDS
1.2.4 Other Systems
1.3 Artificial Pancreas Devices Systems by Application
1.3.1 Global Artificial Pancreas Devices Systems Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.4 Global Artificial Pancreas Devices Systems 麻豆原创 Estimates and Forecasts (2020-2031)
1.4.1 Global Artificial Pancreas Devices Systems 麻豆原创 Size in Value Growth Rate (2020-2031)
1.4.2 Global Artificial Pancreas Devices Systems 麻豆原创 Size in Volume Growth Rate (2020-2031)
1.4.3 Global Artificial Pancreas Devices Systems Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 麻豆原创 Size and Prospective by Region
2.1 Global Artificial Pancreas Devices Systems 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2 Global Artificial Pancreas Devices Systems Retrospective 麻豆原创 Scenario by Region (2020-2025)
2.2.1 Global Artificial Pancreas Devices Systems Sales 麻豆原创 Share by Region (2020-2025)
2.2.2 Global Artificial Pancreas Devices Systems Revenue 麻豆原创 Share by Region (2020-2025)
2.3 Global Artificial Pancreas Devices Systems 麻豆原创 Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Artificial Pancreas Devices Systems Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Artificial Pancreas Devices Systems Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging 麻豆原创 Analysis
2.4.1 North America Artificial Pancreas Devices Systems 麻豆原创 Size and Prospective (2020-2031)
2.4.2 Europe Artificial Pancreas Devices Systems 麻豆原创 Size and Prospective (2020-2031)
3 Global 麻豆原创 Size by Type
3.1 Global Artificial Pancreas Devices Systems Historic 麻豆原创 Review by Type (2020-2025)
3.1.1 Global Artificial Pancreas Devices Systems Sales by Type (2020-2025)
3.1.2 Global Artificial Pancreas Devices Systems Revenue by Type (2020-2025)
3.1.3 Global Artificial Pancreas Devices Systems Price by Type (2020-2025)
3.2 Global Artificial Pancreas Devices Systems 麻豆原创 Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Artificial Pancreas Devices Systems Sales Forecast by Type (2026-2031)
3.2.2 Global Artificial Pancreas Devices Systems Revenue Forecast by Type (2026-2031)
3.2.3 Global Artificial Pancreas Devices Systems Price Forecast by Type (2026-2031)
3.3 Different Types Artificial Pancreas Devices Systems Representative Players
4 Global 麻豆原创 Size by Application
4.1 Global Artificial Pancreas Devices Systems Historic 麻豆原创 Review by Application (2020-2025)
4.1.1 Global Artificial Pancreas Devices Systems Sales by Application (2020-2025)
4.1.2 Global Artificial Pancreas Devices Systems Revenue by Application (2020-2025)
4.1.3 Global Artificial Pancreas Devices Systems Price by Application (2020-2025)
4.2 Global Artificial Pancreas Devices Systems 麻豆原创 Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Artificial Pancreas Devices Systems Sales Forecast by Application (2026-2031)
4.2.2 Global Artificial Pancreas Devices Systems Revenue Forecast by Application (2026-2031)
4.2.3 Global Artificial Pancreas Devices Systems Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Artificial Pancreas Devices Systems Application
5 Competition Landscape by Players
5.1 Global Artificial Pancreas Devices Systems Sales by Players (2020-2025)
5.2 Global Top Artificial Pancreas Devices Systems Players by Revenue (2020-2025)
5.3 Global Artificial Pancreas Devices Systems 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Artificial Pancreas Devices Systems as of 2024)
5.4 Global Artificial Pancreas Devices Systems Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Artificial Pancreas Devices Systems, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Artificial Pancreas Devices Systems, Product Type & Application
5.7 Global Key Manufacturers of Artificial Pancreas Devices Systems, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America 麻豆原创: Players, Segments, Downstream and Major Customers
6.1.1 North America Artificial Pancreas Devices Systems Sales by Company
6.1.1.1 North America Artificial Pancreas Devices Systems Sales by Company (2020-2025)
6.1.1.2 North America Artificial Pancreas Devices Systems Revenue by Company (2020-2025)
6.1.2 North America Artificial Pancreas Devices Systems Sales Breakdown by Type (2020-2025)
6.1.3 North America Artificial Pancreas Devices Systems Sales Breakdown by Application (2020-2025)
6.1.4 North America Artificial Pancreas Devices Systems Major Customer
6.1.5 North America 麻豆原创 Trend and Opportunities
6.2 Europe 麻豆原创: Players, Segments, Downstream and Major Customers
6.2.1 Europe Artificial Pancreas Devices Systems Sales by Company
6.2.1.1 Europe Artificial Pancreas Devices Systems Sales by Company (2020-2025)
6.2.1.2 Europe Artificial Pancreas Devices Systems Revenue by Company (2020-2025)
6.2.2 Europe Artificial Pancreas Devices Systems Sales Breakdown by Type (2020-2025)
6.2.3 Europe Artificial Pancreas Devices Systems Sales Breakdown by Application (2020-2025)
6.2.4 Europe Artificial Pancreas Devices Systems Major Customer
6.2.5 Europe 麻豆原创 Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Medtronic
7.1.1 Medtronic Company Information
7.1.2 Medtronic Business Overview
7.1.3 Medtronic Artificial Pancreas Devices Systems Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Medtronic Artificial Pancreas Devices Systems Products Offered
7.1.5 Medtronic Recent Development
7.2 Bigfoot Biomedical
7.2.1 Bigfoot Biomedical Company Information
7.2.2 Bigfoot Biomedical Business Overview
7.2.3 Bigfoot Biomedical Artificial Pancreas Devices Systems Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Bigfoot Biomedical Artificial Pancreas Devices Systems Products Offered
7.2.5 Bigfoot Biomedical Recent Development
7.3 Beta Bionics
7.3.1 Beta Bionics Company Information
7.3.2 Beta Bionics Business Overview
7.3.3 Beta Bionics Artificial Pancreas Devices Systems Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Beta Bionics Artificial Pancreas Devices Systems Products Offered
7.3.5 Beta Bionics Recent Development
7.4 Admetsys
7.4.1 Admetsys Company Information
7.4.2 Admetsys Business Overview
7.4.3 Admetsys Artificial Pancreas Devices Systems Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Admetsys Artificial Pancreas Devices Systems Products Offered
7.4.5 Admetsys Recent Development
7.5 Insulet
7.5.1 Insulet Company Information
7.5.2 Insulet Business Overview
7.5.3 Insulet Artificial Pancreas Devices Systems Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Insulet Artificial Pancreas Devices Systems Products Offered
7.5.5 Insulet Recent Development
7.6 Tandem Diabetes Care
7.6.1 Tandem Diabetes Care Company Information
7.6.2 Tandem Diabetes Care Business Overview
7.6.3 Tandem Diabetes Care Artificial Pancreas Devices Systems Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Tandem Diabetes Care Artificial Pancreas Devices Systems Products Offered
7.6.5 Tandem Diabetes Care Recent Development
7.7 Defymed
7.7.1 Defymed Company Information
7.7.2 Defymed Business Overview
7.7.3 Defymed Artificial Pancreas Devices Systems Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Defymed Artificial Pancreas Devices Systems Products Offered
7.7.5 Defymed Recent Development
8 Artificial Pancreas Devices Systems Manufacturing Cost Analysis
8.1 Artificial Pancreas Devices Systems Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Artificial Pancreas Devices Systems
8.4 Artificial Pancreas Devices Systems Industrial Chain Analysis
9 麻豆原创ing Channel, Distributors and Customers
9.1 麻豆原创ing Channel
9.2 Artificial Pancreas Devices Systems Distributors List
9.3 Artificial Pancreas Devices Systems Customers
10 Artificial Pancreas Devices Systems 麻豆原创 Dynamics
10.1 Artificial Pancreas Devices Systems Industry Trends
10.2 Artificial Pancreas Devices Systems 麻豆原创 Drivers
10.3 Artificial Pancreas Devices Systems 麻豆原创 Challenges
10.4 Artificial Pancreas Devices Systems 麻豆原创 Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 麻豆原创 Size Estimation
12.1.1.3 麻豆原创 Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer

Companies Mentioned:

Medtronic
Bigfoot Biomedical
Beta Bionics
Admetsys
Insulet
Tandem Diabetes Care
Defymed

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.